Fertility-sparing approach for endometrial cancer: the role of office hysteroscopy

Minim Invasive Ther Allied Technol. 2021 Oct;30(5):296-303. doi: 10.1080/13645706.2021.1949353. Epub 2021 Jul 22.

Abstract

Endometrial cancer is the most common gynecologic malignancy in developed countries, with increasing incidence among younger, nulliparous patients. These epidemiological shifts are attributed to increasing rates of obesity, in combination with delayed childbearing. This highlights a need for fertility-sparing options for individuals who wish to delay standard surgical management with hysterectomy, bilateral salpingoophorectomy, and assessment of pelvic/para-aortic lymph nodes. Careful consideration should be taken to select which patients are suitable candidates for fertility-sparing methods. Typically, these are patients found to have FIGO grade 1 tumors of the endometrioid subtype without myometrial invasion. Currently, conservative treatment options include the use of oral progestins and levonorgestrel-releasing intrauterine devices, with an emerging role for hysteroscopy for direct visualization of the uterine cavity, targeted tissue sampling, and tumor resection. This paper aims to highlight the role of office hysteroscopy for diagnosis, hysteroscopic tumor resection, and follow-up in suitable endometrial cancer patients who wish to preserve their uterus until childbearing is complete.

Keywords: Endometrial cancer; conservative management; fertility-sparing; hysteroscopy; office hysteroscopy.

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use
  • Endometrial Neoplasms* / surgery
  • Female
  • Fertility
  • Fertility Preservation*
  • Humans
  • Hysteroscopy
  • Pregnancy

Substances

  • Antineoplastic Agents, Hormonal